BlackRock, Inc. Amends Schedule 13G/A for EyePoint Pharmaceuticals, Inc.

BlackRock, Inc. has filed an amendment to its Schedule 13G/A for EyePoint Pharmaceuticals, Inc., reporting a decrease in its ownership. As of September 30, 2025, BlackRock beneficially owns 4,485,402 shares of EyePoint Pharmaceuticals' common stock, representing 6.5% of the total outstanding shares. This marks a decrease of 1,213,601 shares (21.295%) from its previous filing. The filing indicates that BlackRock acquired and holds these securities in the ordinary course of business and not for the purpose of influencing control of the issuer. The amendment includes certifications and exhibits, such as a Power of Attorney and details on subsidiary identification and classification.